In Vaccines for the 21st Century: A Tool for Decisionmaking (Stratton, K
Conclusion This comprehensive review highlights the therapeutic potential of GLP-1 and its analogs in the management of metabolic disorders, particularly T2DM
The molecule consists of a modified GLP-1 analog, containing three key amino acid substitutions: Ala8Gly, Gly22Glu, and Arg36Gly, covalently fused to the Fc (constant) region of human immunoglobulin G subclass 4 (IgG4) (Fig
a biologically active form GLP-1-(736) amide and an inactive form GLP-1-(1-37)
ARD-201, planned fixed-dose combination of ARD-101 with a DPP-4 inhibitor for obesity
Most importantly, it does not affect the folding stability of the conjugated protein